12 treatment settings, 7 with more than one named option. Each section lays out the options the standard of care names, what each is for, the trials behind them with their recorded results, the side effects and cautions on record, and questions to ask. Built from the cancer page's standard-of-care rows; nothing here is advice for your case.
Surgery + adjuvant capecitabine.
This setting names no product or technology record yet; the approach above is the standard as written. Ask your team which specific treatments they mean.
No trial record is attached to this row yet. The trials tab lists what is recruiting and the landmark trials for this cancer.
No side-effect rates or interaction flags are recorded for these options yet. The side-effect lookup and interaction checker cover the products that have them.
Add these to your appointment list, or take the full question set for this cancer.
Gem-cis + PD-(L)1; targeted therapy by genotype second line.
A PD-L1 blocker that became standard after chemoradiation for stage III lung cancer, and now in bladder, biliary, and gastric cancers.
Pembrolizumab is an antibody that blocks PD-1. Its U.S. labelled uses depend on cancer, treatment setting and regimen; immune-mediated harms can occur.
Zanidatamab (Ziihera) is an antibody that grabs HER2 at two different spots, approved for HER2+ bile duct cancer and, in the US since August 2026, as first treatment for advanced HER2+ stomach and oesophageal adenocarcinoma.
Zenocutuzumab is the first drug for cancers driven by NRG1 gene fusions, working by blocking HER3 from receiving its growth signal.
Trastuzumab deruxtecan (Enhertu) is an ADC that redefined HER2 by working in tumours with low levels of the protein, and in 2026 moved into early-stage breast cancer.
No trial record is attached to this row yet. The trials tab lists what is recruiting and the landmark trials for this cancer.
| Side effect | Any grade | Grade 3+ |
|---|---|---|
| Pneumonitis (any cause, PACIFIC) · vs 12.8% placebo; 1.1% fatal | 18.3% | - |
Rates from the label or pivotal trial as recorded on the product page; each grade 3+ figure links to its source.
| Side effect | Any grade | Grade 3+ |
|---|---|---|
| Hypothyroidism (immune-mediated) · Pooled monotherapy data, >2,800 patients | 8% | - |
| Pneumonitis (immune-mediated) · Pooled monotherapy data, >2,800 patients | 3.4% | - |
| Colitis (immune-mediated) · Pooled monotherapy data, >2,800 patients | 1.7% | - |
| Hepatitis (immune-mediated) · Pooled monotherapy data, >2,800 patients | 0.7% | - |
Rates from the label or pivotal trial as recorded on the product page; each grade 3+ figure links to its source.
| Side effect | Any grade | Grade 3+ |
|---|---|---|
| Neutropenia · DESTINY-Breast03/04; all-grade rates ≥20% per label | - | 18% |
| Nausea · DESTINY-Breast03/04; all-grade rates ≥20% per label | - | 7% |
| Anaemia · DESTINY-Breast03/04; all-grade rates ≥20% per label | - | 7% |
| Fatigue · DESTINY-Breast03/04; all-grade rates ≥20% per label | - | 6% |
Rates from the label or pivotal trial as recorded on the product page; each grade 3+ figure links to its source.
Add these to your appointment list, or take the full question set for this cancer.
Contrast CT/MRI with MRCP; ERCP or EUS-guided biopsy; molecular profiling (DNA + RNA NGS) for all advanced disease; biliary drainage if jaundiced.
Sequencing hundreds of cancer genes at once from a biopsy to find the mutations a drug can target.
RNA sequencing measures captured RNA messages and, with a suitable library and analysis, can examine transcript joins.
A small tube placed by endoscope or through the skin reopens a blocked bile duct, relieving jaundice so chemotherapy can be given.
Magnetic resonance imaging uses a magnetic field and radio waves for tissue images, including selected high-risk breast screening. Enhancement and volume do not directly count living cancer cells.
No trial record is attached to this row yet. The trials tab lists what is recruiting and the landmark trials for this cancer.
Add these to your appointment list, or take the full question set for this cancer.
Margin-negative resection (hepatectomy, Whipple, or radical cholecystectomy) with lymphadenectomy; adjuvant capecitabine 6 months (BILCAP).
Surgeons operate through small incisions using robotic arms with tremor-free precision and 3D vision.
OS 51.1 vs 36.4 months; ITT HR 0.81 (p=0.097), per-protocol HR 0.75.
Add these to your appointment list, or take the full question set for this cancer.
Neoadjuvant chemoradiation then liver transplantation (Mayo protocol) at experienced centres.
Replacing the whole diseased liver cures both the cancer and the cirrhosis underneath it, for patients whose tumours are small enough.
No trial record is attached to this row yet. The trials tab lists what is recruiting and the landmark trials for this cancer.
Add these to your appointment list, or take the full question set for this cancer.
Gemcitabine-cisplatin + durvalumab (TOPAZ-1) or + pembrolizumab (KEYNOTE-966); zanidatamab added in HER2+ disease within HERIZON-BTC-302.
Gemcitabine plus cisplatin has been the chemotherapy backbone for bile duct cancer since 2010 and is now given with immunotherapy.
A PD-L1 blocker that became standard after chemoradiation for stage III lung cancer, and now in bladder, biliary, and gastric cancers.
Pembrolizumab is an antibody that blocks PD-1. Its U.S. labelled uses depend on cancer, treatment setting and regimen; immune-mediated harms can occur.
Averages across everyone diagnosed, often years ago. A median is the middle of a group: half the people counted lived longer than the figure shown, and some lived far longer. Your stage, subtype, age, fitness and the treatment you receive matter more than the average, and the numbers are improving quickly.
OS 12.7 vs 10.9 months, HR 0.83.
No headline result recorded yet.
| Side effect | Any grade | Grade 3+ |
|---|---|---|
| Neutropenia (grade 3-4) · TOPAZ-1, placebo plus gemcitabine-cisplatin arm, laboratory values (durvalumab US label); the ABC-02 figures could not be checked against the paper | - | 49% |
| Fatigue · TOPAZ-1, placebo plus gemcitabine-cisplatin arm (n=342), durvalumab US label | 43% | 6% |
Rates from the label or pivotal trial as recorded on the product page; each grade 3+ figure links to its source.
| Side effect | Any grade | Grade 3+ |
|---|---|---|
| Pneumonitis (any cause, PACIFIC) · vs 12.8% placebo; 1.1% fatal | 18.3% | - |
Rates from the label or pivotal trial as recorded on the product page; each grade 3+ figure links to its source.
| Side effect | Any grade | Grade 3+ |
|---|---|---|
| Hypothyroidism (immune-mediated) · Pooled monotherapy data, >2,800 patients | 8% | - |
| Pneumonitis (immune-mediated) · Pooled monotherapy data, >2,800 patients | 3.4% | - |
| Colitis (immune-mediated) · Pooled monotherapy data, >2,800 patients | 1.7% | - |
| Hepatitis (immune-mediated) · Pooled monotherapy data, >2,800 patients | 0.7% | - |
Rates from the label or pivotal trial as recorded on the product page; each grade 3+ figure links to its source.
Add these to your appointment list, or take the full question set for this cancer.
Pemigatinib or futibatinib; tinengotinib in FIRST-308 after progression.
Pemigatinib was the first targeted therapy for bile duct cancer, for tumours with an FGFR2 gene fusion.
Futibatinib is a covalent FGFR inhibitor for FGFR2-fusion bile duct cancer, with the highest response rate of the first-generation drugs.
A next-generation FGFR inhibitor designed to work after pemigatinib or futibatinib stop working, now in a global phase 3.
ORR 37%; PFS 7.0 months; OS 17.5 months.
ORR 42%; PFS 9.0 months; OS 21.7 months.
No headline result recorded yet.
| Side effect | Any grade | Grade 3+ |
|---|---|---|
| Diarrhoea · FIGHT-202 (n=146), US label | 47% | 2.7% |
| Nail toxicity · FIGHT-202 (n=146), US label | 43% | 2.1% |
| Retinal pigment epithelial detachment (serous retinal detachment) · Across 635 patients given 13.5 mg in clinical trials, US label | 11% | 1.3% |
| Hyperphosphataemia · FIGHT-202 (n=146), US label | 60% | 0% |
Rates from the label or pivotal trial as recorded on the product page; each grade 3+ figure links to its source.
| Side effect | Any grade | Grade 3+ |
|---|---|---|
| Hyperphosphataemia · Laboratory phosphate increase in FOENIX-CCA2 (Study TAS-120-101, n=103), US label; the NEJM report gives treatment-related grade 3 hyperphosphataemia as 30% | 97% | 39% |
| Dry mouth · FOENIX-CCA2 (n=103), US label | 35% | 0% |
| Alopecia · FOENIX-CCA2 (n=103), US label | 34% | 0% |
Rates from the label or pivotal trial as recorded on the product page; each grade 3+ figure links to its source.
Add these to your appointment list, or take the full question set for this cancer.
Ivosidenib (ClarIDHy).
The first drug to block a mutant metabolic enzyme in cancer. With azacitidine it tripled survival in IDH1-mutated AML that could not take intensive chemotherapy.
PFS HR 0.37; crossover-adjusted OS HR 0.49.
| Side effect | Any grade | Grade 3+ |
|---|---|---|
| Neutropenia · AGILE, ivosidenib with azacitidine (16% with placebo and azacitidine) | - | 27% |
| QT prolongation · AGILE, ivosidenib with azacitidine, N=71 (7% with placebo); US label | 20% | 10% |
| Differentiation syndrome · AGILE, ivosidenib with azacitidine (8% with placebo and azacitidine); the US label counts 15% | 14% | - |
| Leukocytosis · AGILE, ivosidenib with azacitidine, N=71 (1% with placebo); US label | 13% | - |
Rates from the label or pivotal trial as recorded on the product page; each grade 3+ figure links to its source.
Add these to your appointment list, or take the full question set for this cancer.
Zanidatamab (IHC 3+, as licensed by the FDA and EMA); trastuzumab deruxtecan (IHC 3+, tumour-agnostic).
Zanidatamab (Ziihera) is an antibody that grabs HER2 at two different spots, approved for HER2+ bile duct cancer and, in the US since August 2026, as first treatment for advanced HER2+ stomach and oesophageal adenocarcinoma.
Trastuzumab deruxtecan (Enhertu) is an ADC that redefined HER2 by working in tumours with low levels of the protein, and in 2026 moved into early-stage breast cancer.
No trial record is attached to this row yet. The trials tab lists what is recruiting and the landmark trials for this cancer.
| Side effect | Any grade | Grade 3+ |
|---|---|---|
| Neutropenia · DESTINY-Breast03/04; all-grade rates ≥20% per label | - | 18% |
| Nausea · DESTINY-Breast03/04; all-grade rates ≥20% per label | - | 7% |
| Anaemia · DESTINY-Breast03/04; all-grade rates ≥20% per label | - | 7% |
| Fatigue · DESTINY-Breast03/04; all-grade rates ≥20% per label | - | 6% |
Rates from the label or pivotal trial as recorded on the product page; each grade 3+ figure links to its source.
Add these to your appointment list, or take the full question set for this cancer.
Zenocutuzumab (NRG1 fusion, approved 2026); dabrafenib-trametinib (BRAF V600E); pembrolizumab or dostarlimab (MSI-H/dMMR); larotrectinib/entrectinib (NTRK).
Zenocutuzumab is the first drug for cancers driven by NRG1 gene fusions, working by blocking HER3 from receiving its growth signal.
Dabrafenib plus trametinib is the BRAF-plus-MEK pill combination, approved for BRAF V600E lung cancer and, since 2022, for any solid tumour with that mutation.
Pembrolizumab is an antibody that blocks PD-1. Its U.S. labelled uses depend on cancer, treatment setting and regimen; immune-mediated harms can occur.
Dostarlimab is a PD-1 blocker famous for making rectal cancer disappear without surgery in every patient with a mismatch-repair-deficient tumour in the first study; in the larger trial behind its 2026 approval about half to two thirds of patients held a complete response for a year.
No trial record is attached to this row yet. The trials tab lists what is recruiting and the landmark trials for this cancer.
| Side effect | Any grade | Grade 3+ |
|---|---|---|
| Hypothyroidism (immune-mediated) · Pooled monotherapy data, >2,800 patients | 8% | - |
| Pneumonitis (immune-mediated) · Pooled monotherapy data, >2,800 patients | 3.4% | - |
| Colitis (immune-mediated) · Pooled monotherapy data, >2,800 patients | 1.7% | - |
| Hepatitis (immune-mediated) · Pooled monotherapy data, >2,800 patients | 0.7% | - |
Rates from the label or pivotal trial as recorded on the product page; each grade 3+ figure links to its source.
Add these to your appointment list, or take the full question set for this cancer.
FOLFOX (ABC-06, modest benefit); liposomal irinotecan/5-FU had conflicting results (NIFTY positive, NALIRICC negative); clinical trials preferred.
Cytotoxic chemotherapy can kill cancer cells or stop their growth by disturbing cell processes. Healthy cells can be affected too, and each drug and regimen needs its own evidence.
OS 6.9 vs 8.2 months; not improved.
Add these to your appointment list, or take the full question set for this cancer.
Y-90 radioembolisation, hepatic arterial infusion pump chemotherapy, or SBRT at specialised centres; no phase 3 proof of survival benefit.
Millions of tiny radioactive glass or resin beads are injected into the liver artery, lodging in the tumour and irradiating it from within.
Stereotactic body radiotherapy delivers a high dose per treatment to a defined body target using specialised localisation and verification. A short schedule alone does not identify it or establish safety.
No trial record is attached to this row yet. The trials tab lists what is recruiting and the landmark trials for this cancer.
Add these to your appointment list, or take the full question set for this cancer.